Oncolytics Biotech Receives FDA Fast Track Designation For Pelareorep In Advanced Anal Cancer

Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on developing immunotherapy treatments for cancer, has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to pelareorep in combination with a checkpoint inhibitor. The designation is for the treatment of patients with inoperable, locally recurrent, or metastatic squamous cell carcinoma of the anal canal (SCAC) whose disease has progressed after, or who were unable to tolerate, one or more previous lines of systemic therapy.

The FDA's Fast Track designation is intended to speed up the development and review of therapies that address serious diseases with limited treatment options. It provides several regulatory advantages, including more frequent interactions with the FDA during clinical development, the opportunity to submit sections of a future Biologics License Application (BLA) on a rolling basis, and potential eligibility for Priority Review if the therapy meets the required standards. Oncolytics believes this designation further supports pelareorep's potential to address a significant unmet medical need in advanced SCAC.

The announcement follows a productive meeting between Oncolytics and the FDA in April 2026, where the company received encouraging feedback on its proposed registration strategy for pelareorep. Based on the agency's guidance, Oncolytics believes it now has a clear regulatory pathway to advance the therapy into a pivotal clinical study for patients with second-line and later-stage anal cancer. Chief Executive Officer Jared Kelly said the latest designation marks another important regulatory milestone and reflects the company's progress over the past year, including additional Fast Track designations, stronger intellectual property protection, and continued positive clinical results across its gastrointestinal oncology programs.

The FDA's decision was supported by encouraging results from the company's ongoing GOBLET clinical study, which is evaluating pelareorep in combination with a checkpoint inhibitor in patients with advanced SCAC whose disease had progressed after previous treatment. The study demonstrated an objective response rate of approximately 30%, more than double the historical response rates reported in this patient population. It also showed a median duration of response of around 15.5 months, compared with approximately 9.5 months historically, while the 12-month overall survival rate reached 82%, significantly higher than the previously reported rate of 45.7%.

Although checkpoint inhibitors combined with chemotherapy have become the standard first-line treatment for advanced SCAC, there are currently no FDA-approved therapies available for patients whose disease progresses after receiving this regimen. While checkpoint inhibitors are approved as single-agent treatment following progression after platinum-based chemotherapy alone, no therapy has yet been approved for patients who progress after today's first-line standard of care. This continues to represent a significant unmet medical need and a potential U.S. commercial opportunity estimated at nearly $1 billion annually.

The Fast Track designation for SCAC is the third gastrointestinal cancer indication for which pelareorep has received this recognition from the FDA. The therapy previously received Fast Track designation for KRAS-mutated metastatic colorectal cancer in February 2026 and pancreatic cancer in late 2022. Together, these designations further strengthen the company's strategy of advancing pelareorep across multiple gastrointestinal cancers while supporting its efforts to bring new treatment options to patients with limited therapeutic choices.